Intercept Pharma (ICPT) Misses Q4 EPS by $1.10, Revenue Tops Views
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Wedbush Maintains Outperform Rating and $224 PT on Intercept Pharmaceuticals (ICPT) Following Positive 2017 Data Readouts
February 24, 2017 8:40 AM ESTWedbush Securities analyst Liana Moussatos reiterates Outperform rating and $224 price target on Intercept Pharmaceuticals Inc. (NASDAQ: ICPT), suggesting 2017 data readouts provide near-term catalysts for investors, as the company provided 2016 fourth quarter Ocaliva sales above the Street.
Moussatos comments, "We believe several clinical... More
Oppenheimer Reiterates Outperform Rating and $200 PT on Intercept Pharmaceuticals (ICPT) on Strong 4Q Ocaliva Sales
February 24, 2017 8:32 AM ESTOppenheimer and Co. analyst Jay Olson reiterates Outperform rating and $200 price target on Intercept Pharmaceuticals Inc. (NASDAQ: ICPT), suggesting the global launch is ramping up, as the company delivered 2016 fourth quarter Ocaliva sales above consensus expectations.
Olson comments, "ICPT announced 4Q results with... More
Intercept Pharmaceuticals (ICPT) PT Raised to $221 at BMO Capital
February 24, 2017 8:26 AM ESTBMO Capital raised its price target on Intercept Pharmaceuticals (NASDAQ: ICPT) to $221.00 (from $198.00) while maintaining a Outperform rating. ICPT reported 4Q Ocaliva sales of $13.4 million, of which $3.9 million were deferred revenues associated with inventory stocking at the distributor level.
Analyst Ian Somaiya... More
